← Back to Search

68Ga-FAPI PET Scan for Cancer

Phase 2
Waitlist Available
Led By Carina A Mari, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trial is testing the use of a radioactive substance called 68Ga-FAPI as a possible cancer-detecting agent. The substance attaches to cancer-activated cells, and by using a PET scanner, doctors may be able to see smaller tumors than with standard imaging.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of 68Ga-FAPI PET

Trial Design

1Treatment groups
Experimental Treatment
Group I: 68Ga-FAPI PET/CTExperimental Treatment3 Interventions
Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography (PET) scan
2016
Completed Phase 2
~190
68Ga-FAPI
2022
Completed Phase 2
~30
Computed Tomography (CT) scan
2017
Completed Phase 3
~180

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,408 Previous Clinical Trials
17,343,218 Total Patients Enrolled
Carina A Mari, MDPrincipal InvestigatorStanford Universiy

Media Library

68Ga-FAPI Clinical Trial Eligibility Overview. Trial Name: NCT04023240 — Phase 2
Cancer Research Study Groups: 68Ga-FAPI PET/CT
Cancer Clinical Trial 2023: 68Ga-FAPI Highlights & Side Effects. Trial Name: NCT04023240 — Phase 2
68Ga-FAPI 2023 Treatment Timeline for Medical Study. Trial Name: NCT04023240 — Phase 2
~16 spots leftby May 2025